Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Altimmune, Inc. (ALT) had Consolidated Net Income/Loss of $-88.09M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.04M |
|
$-88.09M |
|
-- |
|
$0.04M |
|
$94.53M |
|
$-94.49M |
|
$5.71M |
|
$-88.77M |
|
$-88.77M |
|
$-88.09M |
|
$-88.09M |
|
|
Consolidated Net Income/Loss |
$-88.09M |
$-88.09M |
|
$-94.49M |
|
$-96.24M |
|
88.10M |
|
88.10M |
|
$-1.00 |
|
$-1.00 |
|
| Balance Sheet Financials | |
$278.19M |
|
$0.31M |
|
$1.74M |
|
$279.93M |
|
$15.00M |
|
$34.29M |
|
$40.04M |
|
$55.04M |
|
$224.89M |
|
$224.89M |
|
$224.89M |
|
110.88M |
|
| Cash Flow Statement Financials | |
$-67.53M |
|
$-132.47M |
|
$206.84M |
|
$36.97M |
|
$43.80M |
|
$6.83M |
|
$16.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.55 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
100.00% |
|
-230461.00% |
|
-230461.00% |
|
-234726.80% |
|
-216522.00% |
|
-214861.00% |
|
$-67.55M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.02 |
|
0.02M |
|
-39.17% |
|
-39.17% |
|
-31.47% |
|
-33.99% |
|
$2.03 |
|
$-0.77 |
|
$-0.77 |
|